Zepbound vs Mounjaro: Real-World Evidence Comparison

What Is the Difference Between Zepbound and Mounjaro?

Zepbound and Mounjaro are brand names for the same drug: tirzepatide. Eli Lilly manufactures both, and the injector pens, concentrations, and dose titration schedules are interchangeable. The FDA issued two separate approvals because the clinical trial programs targeted different patient populations and different primary endpoints.

Why Two Brands for One Molecule?

The FDA's drug-approval process is indication-specific. Eli Lilly ran the SURPASS program to demonstrate glycemic benefit in adults with type 2 diabetes, which earned Mounjaro its approval in May 2022 under NDA 215866. [1] Separately, the SURMOUNT program tested higher-dose tirzepatide in adults with obesity or overweight plus at least one weight-related comorbidity, producing Zepbound's approval in November 2023. [2]

Having two labels matters for insurance billing, not pharmacology. A commercial payer that covers Mounjaro for diabetes may refuse Zepbound for weight loss, or vice versa, even though the prescriber writes the same milligram dose either way.

Shared Mechanism: GIP and GLP-1 Dual Agonism

Tirzepatide binds both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. GLP-1 receptor activation slows gastric emptying, suppresses glucagon, and promotes satiety. GIP receptor activation may augment insulin secretion and alter adipose tissue metabolism in ways that single GLP-1 agonists like semaglutide do not replicate. [3]

That dual mechanism is the probable reason tirzepatide produces larger weight reductions than semaglutide 2.4 mg head-to-head in the SURMOUNT-5 trial (published January 2025), where tirzepatide 10 mg or 15 mg produced 20.2% weight loss vs. 13.7% on semaglutide 2.4 mg at 72 weeks (P<0.001). [4]

Clinical Trial Evidence: SURMOUNT and SURPASS Programs

The evidence base for tirzepatide spans six completed phase 3 trials. The two most cited in the context of this comparison are SURMOUNT-1 and SURPASS-2.

SURMOUNT-1 (Obesity, No Diabetes)

SURMOUNT-1 enrolled 2,539 adults with BMI ≥30 or BMI ≥27 with at least one weight-related condition (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) but without type 2 diabetes. Participants received weekly tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo for 72 weeks.

At the highest dose (15 mg), mean weight loss reached 22.5% of body weight, compared with 2.4% on placebo. [5] The 10 mg arm produced 21.4% loss and the 5 mg arm 16.0%. Roughly 63% of participants on 15 mg achieved at least 20% body weight reduction, a threshold that rivals outcomes from some bariatric procedures.

The NEJM 2022 publication by Jastreboff et al. Reported: "Tirzepatide resulted in substantial and sustained reductions in body weight across all doses." [5]

SURPASS-2 (Type 2 Diabetes vs. Semaglutide 1 mg)

SURPASS-2 (N=1,879) compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg weekly in adults with inadequately controlled type 2 diabetes on metformin. At 40 weeks, tirzepatide 15 mg reduced HbA1c by 2.01 percentage points vs. 1.86 percentage points for semaglutide 1 mg. [6] Weight loss in the 15 mg arm was 12.4 kg vs. 6.2 kg on semaglutide.

SURPASS-2 forms the backbone of Mounjaro's diabetes label and explains why clinicians treating patients with both obesity and type 2 diabetes sometimes prefer to bill under the Mounjaro indication even when weight loss is the primary goal.

SURMOUNT-MMO (Cardiovascular Outcomes, Ongoing)

The SURMOUNT-MMO trial is investigating whether tirzepatide reduces major adverse cardiovascular events in adults with obesity and established cardiovascular disease. Data are expected in 2025 to 2026. If positive, this outcome data will likely expand Zepbound's label, similar to the semaglutide SELECT trial (NEJM 2023), which reduced MACE by 20% in the semaglutide arm. [7] Clinicians prescribing for cardiovascular risk reduction should watch for that readout.

Real-World Evidence: What Happens Outside Trials?

Phase 3 trials use highly selected populations and enforce strict adherence monitoring. Real-world data from claims databases, electronic health records, and pharmacy networks offer a different view.

Adherence and Persistence

A 2024 analysis published in JAMA Internal Medicine examined GLP-1 and dual agonist persistence in commercially insured U.S. Adults. At 12 months, fewer than 45% of patients who started a GLP-1 class agent remained on therapy. [8] Tirzepatide users showed modestly higher persistence than semaglutide users in the same dataset, possibly because of greater early weight loss reinforcing continued use.

Persistence matters clinically. Trials like SURMOUNT-4 demonstrated that discontinuing tirzepatide after 36 weeks of treatment led to weight regain of approximately 14 percentage points over the following 52 weeks, compared with continued weight loss in the maintenance group. [9] The drug suppresses appetite only while it is active.

Weight Loss in Routine Clinical Practice

Real-world weight outcomes tend to run 3 to 6 percentage points lower than trial outcomes, for two reasons: patient populations in practice have more comorbidities that limit dose escalation, and adherence is lower. Published real-world cohort data from a 2024 Obesity journal analysis of 938 adults starting tirzepatide in primary care settings found mean 6-month weight loss of 14.7%, compared with the 16.0% to 22.5% range seen across SURMOUNT-1 dose arms over 72 weeks. [10]

No published real-world study has compared Zepbound-labeled prescriptions against Mounjaro-labeled prescriptions on clinical outcomes, because the molecule and dose are identical. Any difference in outcome data would be a product of patient-mix differences (obesity without diabetes vs. Obesity with diabetes) rather than a drug effect.

Side-Effect Profile in Practice

The most common adverse effects in SURMOUNT-1 were nausea (up to 33% on 15 mg), diarrhea (22%), vomiting (20%), and constipation (17%). [5] Real-world pharmacy data confirm similar rates, with gastrointestinal events clustering in the first 4 to 8 weeks of each dose escalation step.

Rare but serious events monitored in both labels include acute pancreatitis, gallbladder disease (cholelithiasis at 2 to 3x baseline rates in trial populations), and medullary thyroid carcinoma risk based on rodent data. The FDA requires a black-box warning about medullary thyroid carcinoma in both the Mounjaro and Zepbound labels, though no human cases have been causally attributed to tirzepatide as of early 2025. [1][2]

Dosing, Titration, and Pen Devices

Both Mounjaro and Zepbound ship in single-dose prefilled autoinjectors. The titration schedule is identical across both labels.

Standard Titration Schedule

| Week | Dose | |---|---| | 1 to 4 | 2.5 mg weekly | | 5 to 8 | 5 mg weekly | | 9 to 12 | 7.5 mg weekly (optional maintenance) | | 13 to 16 | 10 mg weekly (optional maintenance) | | 17 to 20 | 12.5 mg weekly (optional maintenance) | | 21+ | 15 mg weekly (optional maintenance) |

Most prescribers hold patients at a given dose for 4 weeks before escalating. Some patients achieve adequate response at 5 mg or 7.5 mg and never need higher doses. Forcing escalation purely to match trial protocols is not clinically necessary if the patient tolerates the current dose and is meeting their glycemic or weight target.

Self-Injection Technique

Tirzepatide is injected subcutaneously into the abdomen, thigh, or upper arm, rotating sites weekly. Injection site reactions occurred in approximately 3% of SURMOUNT-1 participants. [5] Patients should store pens refrigerated at 36 to 46°F (2 to 8°C) and may keep a pen at room temperature for up to 21 days.

Insurance Coverage and Cost: The Real-World Differentiator

Cost and coverage are the main practical factors separating Zepbound from Mounjaro in clinical practice, not the drug itself.

Mounjaro Coverage

Mounjaro has broader commercial insurance coverage because type 2 diabetes treatments are rarely excluded from pharmacy benefits. The 2024 American Diabetes Association Standards of Care recommend GLP-1 receptor agonists and dual GIP/GLP-1 agonists as second-line agents after metformin for HbA1c reduction and cardiovascular risk reduction. [11] That guideline endorsement has moved most major PBMs to cover Mounjaro with a prior authorization for qualifying patients.

Zepbound Coverage

Zepbound faces a harder insurance path. The Affordable Care Act does not mandate obesity drug coverage, and roughly 30% of commercial plans explicitly exclude weight-loss medications as of 2024. [12] Medicare Part D covered Zepbound starting January 2024 under the Inflation Reduction Act provisions for obesity treatment, though access varies by plan.

Eli Lilly's savings cards can bring Zepbound to as low as $550 per month for eligible commercially insured patients, and Mounjaro to a similar figure. Without insurance or a savings card, both list near $1,060 per four pens per month. Compounded tirzepatide from 503B outsourcing facilities was available during the FDA shortage period and may persist in some markets, though the FDA removed tirzepatide from the shortage list in late 2024. [13]

Formulary Switching

Some insurers cover Mounjaro for a patient with both type 2 diabetes and obesity, but cover Zepbound for the same patient if they are being treated under the obesity indication. Others do the reverse. Prescribers who manage patients on tirzepatide routinely write both brand names on a patient's chart and clarify with the pharmacy which to bill based on the patient's active coverage.

Should You Switch from Zepbound to Mounjaro (or Vice Versa)?

Switching between Zepbound and Mounjaro involves zero pharmacological change. The decision is entirely administrative or financial.

Clinical Reasons to Switch Labels

There is no clinical reason to switch brands if the patient's current supply is uninterrupted and insured. A switch makes sense when:

• The patient's diagnosis changes (e.g., a patient on Zepbound is later diagnosed with type 2 diabetes, opening Mounjaro coverage)
• The patient's insurer changes formularies at renewal
• One brand is available from the dispensing pharmacy and the other is back-ordered
• A new savings program makes one brand substantially cheaper out of pocket

How to Manage the Transition

Because dose, timing, and injection technique are identical, no washout period or dose adjustment is needed when switching labels. The prescriber writes a new prescription with the alternate brand name at the current dose. The patient continues their weekly injection on the same day without interruption.

The American Association of Clinical Endocrinology (AACE) Obesity Clinical Practice Guidelines state that maintaining medication continuity is a top priority in obesity pharmacotherapy because of the demonstrated weight regain seen with discontinuation. [14] A brand switch should not translate into any gap in supply.

What Patients Report

Patients who have switched in either direction consistently report no perceived difference in appetite suppression, injection experience, or side-effect profile. This is expected: the pen design, concentration, and excipients are the same across both brands. Forum data from patient communities, while not a primary source, align with the pharmacological expectation of zero experiential difference.

Who Should Take Tirzepatide Under Which Label?

Mounjaro Is the Correct Label When

• The patient has a confirmed type 2 diabetes diagnosis (HbA1c ≥6.5%, or fasting glucose ≥126 mg/dL on two occasions)
• The payer covers Mounjaro but not Zepbound
• The prescriber's primary goal is HbA1c reduction, with weight loss as a secondary benefit

Zepbound Is the Correct Label When

• The patient has obesity (BMI ≥30) or overweight (BMI ≥27) with a qualifying comorbidity, without type 2 diabetes
• The payer covers Zepbound under an obesity benefit
• Medicare Part D is the payer and the patient's plan covers anti-obesity medications

Patients with type 2 diabetes and obesity qualify under both labels. The prescriber and patient should choose based on coverage verification, not clinical preference.

Tirzepatide vs. Semaglutide: Context for the Comparison

Clinicians comparing Zepbound and Mounjaro often ask where tirzepatide fits relative to semaglutide (Ozempic/Wegovy), the other major GLP-1 class agent.

SURMOUNT-5 (January 2025, N=751) provided the first head-to-head data in patients without diabetes. Tirzepatide 10 mg or 15 mg produced a 47% greater relative weight loss than semaglutide 2.4 mg (20.2% vs. 13.7%) at 72 weeks. [4] Gastrointestinal side effect rates were similar between the two drugs.

For glycemic control, SURPASS-2 showed tirzepatide's superiority to semaglutide 1 mg (not the 2 mg dose), so the glycemic advantage narrows at higher semaglutide doses. [6] The ADA 2024 Standards of Care note that both agents are appropriate for most patients with type 2 diabetes and cardiovascular risk factors, with the choice guided by cost, access, and individual response. [11]